1 Amend 17 Cal. Code of Regs. section 100070 to read:

- 2 § 100070. SCRO Committee Review and Notification.
- 3 (a) CIRM-funded research involving the procurement or use of human oocytes or the 4 creation of human gametes may not commence without SCRO committee review and approval in 5 writing. If CIRM-funded research involves the procurement of human oocytes from a living 6 donor For such SCRO committee review and approval, a member of the committee with 7 expertise in assisted reproduction shall be present. The designated SCRO committee may require 8 that modification be made to proposed research or documentation of compliance with the 9 requirements of subdivision (a)(3) of this regulation as a condition of granting its approval. At a 10 minimum, the SCRO committee shall require the investigator to: 11 (1) Provide an acceptable scientific rationale for the need to procure or use 12 human oocytes or create human gametes. In the case of human oocyte procurement, 13 including a justification for the number needed. If SCNT is proposed a justification for 14 SCNT shall be provided. 15 (2) Demonstrate experience, expertise or training in derivation or culture of 16 human or nonhuman stem cell lines. 17 (3) Provide documentation of compliance with any required review of the 18 proposed research by an IRB, Institutional Animal Care and Use Committee (IACUC), 19 Institutional Bioethics Committee (IBC), or other mandated review. 20 (b) CIRM-funded research involving procurement, creation or use of human blastocysts 21 or embryos may not commence without SCRO committee review and approval in writing. The 22 designated SCRO committee may require that modification be made to proposed research or 100070 Amendments; 2nd Public Notice 10/30/09 1

1 documentation of compliance with the requirements of subdivision (b)(3) of this regulation as a condition of granting its approval. At a minimum, the SCRO committee shall require the 2 3 investigator to: 4 (1) Provide an acceptable scientific rationale for the need to create or use 5 blastocysts or embryos including a justification for the number needed. 6 (2) Demonstrate experience, expertise or training in derivation or culture of 7 human or nonhuman stem cell lines. 8 (3) Provide documentation of compliance with any required review of the 9 proposed research by an IRB, Institutional Animal Care and Use Committee (IACUC), 10 Institutional Bioethics Committee (IBC), or other mandated review. 11 (c) CIRM-funded research with the aim to derive or create a covered stem cell line from 12 human gametes, embryos or products of SCNT involving a human donor nucleus may not 13 commence without SCRO committee review and approval in writing, human subjects research, 14 as defined by Title 45 Code of Federal Regulations, Part 46 (Protection of Human Subjects), 15 revised June 23, 2005, and California Health and Safety Code section 24173 with the aim to 16 create, from sources other than human gametes, blastocysts or embryos, or use a covered stem 17 cell line may not commence with out written notification of the SCRO committee. Research may include animal assays to evaluate pluripotency; however, subsequent introduction of derived 18 19 covered stem cell lines in non-human animals shall be reviewed in accordance with section (e). 20 The designated SCRO committee may require that modification be made to proposed research or 21 documentation of compliance with the requirements of subdivision (c)(4) of this regulation as a 22 condition of granting its approval. At a minimum, the SCRO committee shall require the

10/30/09

1 investigator to: 2 (1) Provide an acceptable scientific rationale for the need to derive a covered stem cell line. 3 4 (2) If SCNT is proposed as a route to generating human stem cell lines, a 5 justification for SCNT shall be provided. (3)(1) Demonstrate experience, expertise or training in derivation or culture of 6 7 human or nonhuman stem cell lines. (4)(2) Provide documentation of compliance with any required review of the 8 9 proposed research by an IRB, Institutional Bioethics Committee (IBC), or other mandated review. 10 11 (5)(3) Document how stem cell lines will be characterized, validated, stored, and 12 distributed to ensure that the confidentiality of the donor(s) is protected. 13 (d) CIRM-funded purely in vitro research utilizing covered stem cell lines or the reprogramming of human somatic cells with the aim to derive or create a covered stem cell line 14 15 may not commence without written notification to the designated SCRO committee. with the aim 16 to create or use a covered stem cell line from non-identifiable cells may not commence with out 17 written notification of the SCRO committee. A statement from the designated institutional 18 official (Title 17, California Code of Regulations, section 100040, subdivision (b)(1)) may be 19 provided in lieu of SCRO committee notification if human somatic cells conform to the requirements of Title 17, California Code of Regulations, section 100080, subdivision (a)(3); or 20 21 the covered stem cell line(s) are recognized by an authorized authority. At a minimum the 22 statement shall certify the:

10/30/09

1	(1) Human somatic cells conform to the requirements of Section 100080(a)(3); or		
2	(2) The covered stem cell lines are recognized by an authorized authority.		
3 4	In addition, the institutional official shall submit documentation of any required review of		
5	the proposed research by an IRB, IACUC, IBC, or other mandated review.		
6			
7	Research may include animal assays to evaluate pluripotency; however, subsequent		
8	introduction of derived covered stem cell lines in non-human animals shall be reviewed in		
9	accordance with subdivision (e) of this regulation. At a minimum, the notification shall:		
10	(1) Provide assurance that all covered stem cell lines have been acceptably		
11	derived.		
12	(2) Provide documentation of compliance with any required review of the		
13	proposed research by an IRB, IACUC, IBC, or other mandated review.		
14	(e) CIRM-funded research introducing covered stem cell lines into non-human animals		
15	or introducing neural-progenitor cells into the brain of non-human animals at any state of		
16	embryonic, fetal, or postnatal development may not commence without SCRO committee review		
17	and approval in writing. The designated SCRO committee may require that modification be		
18	made to proposed research or documentation of compliance with the requirements of subdivision		
19	(e)(3) of this regulation as a condition of granting its approval. The SCRO committee may		
20	establish guidelines and procedures for expedited review of animal research so that review by the		
21	entire SCRO committee is not required. At a minimum, the SCRO committee shall require the		
22	investigator to:		
23	(1) Provide an acceptable scientific rationale for introducing stem cells into non-		

10/30/09

1	human	animals.	

- 2 (2) Provide assurance that all covered stem cell lines have been acceptably
 3 derived.
- 4 (3) Evaluate the probable pattern and effects of differentiation and integration of
 5 the human cells into the nonhuman animal tissues.
- 6 (4) Provide documentation of compliance with any required review of the
 7 proposed research by an IRB, IACUC, IBC, or other mandated review.
- 8 (f) CIRM-funded research introducing stem-cells from covered stem cell lines into a live 9 born human may not commence without SCRO committee review and approval in writing. The 10 designated SCRO committee may require that modification be made to proposed research or 11 documentation of compliance with the requirements of subdivision (f)(4) of this regulation as a 12 condition of granting its approval. At a minimum, the SCRO committee shall require the 13 investigator to:
- 14 (1) Provide an acceptable scientific for rationale introducing stem cells into
 15 humans.
- 16 (2) Provide assurance that all covered stem cell lines have been acceptably
 17 derived.
- 18 (3) Evaluate the probable pattern and effects of differentiation and integration of19 the human cells into the human tissues.
- 20 (4) Provide documentation of compliance with any required review of the
 21 proposed research by an IRB, IACUC, IBC, or other mandated review.
- 22 (g) In cases where SCRO committee approval is required, a SCRO committee shall

10/30/09

1 notify investigators in writing of its decision to approve or disapprove the proposed research 2 activity, or of modifications required to secure SCRO committee approval of the research 3 activity. If the SCRO committee decides to disapprove a research activity, it shall include in its 4 written notification a statement of the reasons for its decision and give the investigator an 5 opportunity to respond in person or in writing. 6 (h) SCRO committee approvals shall be reviewed no less frequently than once per year. 7 The renewal review shall confirm compliance with all applicable rules and regulations. The 8 SCRO committee may establish guidelines and procedures for expedited review of renewals so 9 that review by the entire SCRO committee is not required. 10 Note: Authority cited: Article XXXV, California Constitution; Section 125290.40(j), Health and

11 Safety Code. Reference: Sections 125290.40, 125290.55, Health and Safety Code.